Retatrutide vs BPC-157
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and BPC-157 (Body Protection Compound-157). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | BPC-157 Body Protection Compound-157, PL 14736 |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | Category 2 (pending reclassification) |
| Category | Weight Loss | Recovery & Healing |
| Primary Use | Obesity and weight management | Tissue healing and injury recovery |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $50 - $120/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 250-500mcg daily |
| Frequency | Weekly | Daily |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth factors, and accelerates tissue repair |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Low |
| Clinical Trial Phase | Phase 3 | N/A |
Key Differences
- 1Retatrutide has clinical weight loss data (28.7%), while BPC-157 is not primarily indicated for weight loss.
- 2BPC-157 is generally more affordable ($50 - $120/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 3Retatrutide is dosed weekly, while BPC-157 is daily.
- 4Retatrutide has high-quality evidence, while BPC-157 has low-quality evidence.
- 5They belong to different categories: Retatrutide (Weight Loss) vs BPC-157 (Recovery & Healing).
Which Is Better For...
BPC-157
More budget-friendly option with lower monthly costs
Retatrutide
More convenient dosing schedule (weekly)
BPC-157
Fewer commonly reported side effects
Retatrutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| BPC-157 | $50 - $120/mo | Category 2 (pending reclassification) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. BPC-157 is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while BPC-157 costs $50 - $120/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). BPC-157 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideBPC-157 is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Although not FDA-approved, it has gained significant attention in research a...
View Full BPC-157 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and BPC-157 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.